LRWA
TXMD icon

Long Run Wealth Advisors’s TherapeuticsMD TXMD Stock Holding History

Long Run Wealth Advisors’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-611
Closed -$11K – 97
2022
Q1 		$11K Buy
611
+400
+190% +$6.29K ﹤0.01% 96
2021
Q4 		$4K Buy
+211
New +$6.32K ﹤0.01% 98

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

Long Run Wealth Advisors's TXMD Position: Q2 2022 in Review

Long Run Wealth Advisors sold out of TherapeuticsMD (TXMD) in Q2 2022, closing a stake of 611 shares — an estimated $11K sold.

Long Run Wealth Advisors first reported a position in TXMD in Q4 2021 and held it in 2 quarters. The position peaked at $11K in Q1 2022. 53 funds tracked by Wall St. Rank hold TXMD as of Q2 2022.

  • Long Run Wealth Advisors reported no remaining TherapeuticsMD position as of Q2 2022 after selling out during the quarter.
  • Long Run Wealth Advisors sold 611 TherapeuticsMD shares in Q2 2022, an estimated $11K.
  • Long Run Wealth Advisors first reported a position in TherapeuticsMD in Q4 2021 and held it in 2 quarters.
  • Long Run Wealth Advisors's TherapeuticsMD position peaked at $11K in Q1 2022.
  • 53 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2022.

Based on Long Run Wealth Advisors's 13F filing for Q2 2022, filed 19 Jul 2022.